Short Interest in Elekta AB (publ) (OTCMKTS:EKTAY) Expands By 200.0%

Elekta AB (publ) (OTCMKTS:EKTAY) was the target of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 300 shares, an increase of 200.0% from the January 31st total of 100 shares. Based on an average trading volume of 6,300 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, Sanford C. Bernstein upgraded Elekta AB (publ) from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 29th.

Elekta AB (publ) Stock Up 0.2 %

Shares of Elekta AB (publ) stock traded up $0.01 during trading on Friday, hitting $5.43. 9,765 shares of the stock traded hands, compared to its average volume of 8,953. Elekta AB has a 52-week low of $5.25 and a 52-week high of $8.24. The company has a current ratio of 1.05, a quick ratio of 0.81 and a debt-to-equity ratio of 0.60. The firm has a market cap of $2.08 billion, a P/E ratio of 21.72 and a beta of 1.22. The stock’s fifty day simple moving average is $5.72 and its 200 day simple moving average is $6.07.

Elekta AB (publ) (OTCMKTS:EKTAY) last announced its earnings results on Friday, February 21st. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $416.86 million during the quarter, compared to analyst estimates of $435.89 million. Elekta AB (publ) had a net margin of 5.65% and a return on equity of 11.07%. On average, equities analysts predict that Elekta AB will post 0.36 earnings per share for the current fiscal year.

Elekta AB (publ) Cuts Dividend

The firm also recently declared a dividend, which will be paid on Thursday, March 27th. Shareholders of record on Friday, March 7th will be paid a $0.1072 dividend. The ex-dividend date is Friday, March 7th. Elekta AB (publ)’s dividend payout ratio (DPR) is presently 40.00%.

About Elekta AB (publ)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.